Impact of new treatment strategies on survival in advanced ovarian cancer
Official title: Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
Run by University Hospital, Strasbourg, France · NCT06907771 · Data updated 2026-11-12
This study looks at how new treatment strategies can improve survival for adults with advanced ovarian cancer who have had surgery and chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 130 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | April 22, 2024 |
| Main results expected | December 22, 2025 |
| Study ends | December 22, 2025 |
| Registry record updated | April 2, 2025 |
| Trial ID | NCT06907771 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have undergone specific surgical treatments for advanced ovarian cancer at the University Hospital in Strasbourg.
✕Probably not a fit
Patients with other histological types of ovarian cancer or those at earlier stages of the disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study examines the effects of evolving therapeutic strategies on the survival of patients with advanced ovarian cancer, particularly focusing on those who have undergone radical surgeries and maintenance treatments following neoadjuvant chemotherapy. It targets adult patients diagnosed with high-grade serous carcinoma of ovarian origin at advanced stages (FIGO IIIC or IV) who were treated at the University Hospital in Strasbourg between 2010 and 2022. The study aims to gather data on patient outcomes to assess the effectiveness of these new management approaches.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates for patients with advanced ovarian cancer.
How similar studies have gone: While this study builds on evolving treatment strategies, similar approaches have shown promise in improving outcomes for ovarian cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years old) * Operated on at the HUS between January 1, 2010 and December 31, 2022 * Having undergone primary or interval cytoreductive surgery * Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin Exclusion Criteria: * Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques. * Autres types histologiques de cancer de l'ovaire * Stades de la maladie FIGO I, II, IIIA et IIIC * Chirurgie de clôture.
Where it's running
-
Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Lise LECOINTRE, MD
- Email: lise.lecointre@chu-strasbourg.fr
- Phone: 33 3 88 12 75 10
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.